You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDemecarium
Accession NumberDB00944  (APRD00905)
TypeSmall Molecule
GroupsApproved
DescriptionDemecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle. The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.
Structure
Thumb
Synonyms
Demecarium
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HumorsolMSD
TonilenNot Available
TosmilenNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Demecarium bromide
56-94-0
Thumb
  • InChI Key: YHKBUDZECQDYBR-UHFFFAOYSA-L
  • Monoisotopic Mass: 714.235531466
  • Average Mass: 716.588
DBSALT000567
Categories
UNIIILP8XJ8R5K
CAS numberNot Available
WeightAverage: 556.7797
Monoisotopic: 556.398856172
Chemical FormulaC32H52N4O4
InChI KeyRWZVPVOZTJJMNU-UHFFFAOYSA-N
InChI
InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2
IUPAC Name
N,N,N-trimethyl-3-{[methyl(10-{methyl[3-(trimethylazaniumyl)phenoxycarbonyl]amino}decyl)carbamoyl]oxy}anilinium
SMILES
CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
Pharmacology
IndicationFor the topical treatment of chronic open-angle glaucoma.
Structured Indications Not Available
PharmacodynamicsDemecarium is a long-acting cholinesterase inhibitor and potent miotic. Because of its toxicity, it should be reserved for use in patients with open-angle glaucoma or other chronic glaucomas not satisfactorily controlled with the short-acting miotics and other agents. Application of demecarium to the eye produces intense miosis and ciliary muscle contraction due to inhibition of cholinesterase, allowing acetylcholine to accumulate at sites of cholinergic transmission. These effects are accompanied by increased capillary permeability of the ciliary body and iris, increased permeability of the blood-aqueous barrier, and vasodilation. Myopia may be induced or, if present, may be augmented by the increased refractive power of the lens that results from the accommodative effect of the drug.
Mechanism of actionDemecarium is an indirect-acting parasympathomimetic agent, also known as a cholinesterase inhibitor and anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle (affecting the accommodation reflex and causing a spasm of the focus to near vision). The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure. Of the two actions, the effect on the accommodation reflex is the more transient and generally disappears before termination of the miosis.
TargetKindPharmacological actionActionsOrganismUniProt ID
AcetylcholinesteraseProteinyes
inhibitor
HumanP22303 details
CholinesteraseProteinunknown
inhibitor
HumanP06276 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityThe oral LD50 is 2.96 mg/kg in the mouse. Symptoms of overdose include nausea, vomiting, abdominal cramps, diarrhea, urinary incontinence, salivation, sweating, difficulty in breathing, bradycardia, or cardiac irregularities.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Demecarium.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Demecarium.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Demecarium.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Demecarium.Experimental, Illicit
AcebutololDemecarium may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Demecarium is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Demecarium.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Demecarium.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Demecarium.Experimental
AlprenololDemecarium may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Demecarium.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Demecarium.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Demecarium.Approved
Aop200704Demecarium may increase the bradycardic activities of Aop200704.Investigational
ArecolineThe risk or severity of adverse effects can be increased when Demecarium is combined with Arecoline.Experimental
ArotinololDemecarium may increase the bradycardic activities of Arotinolol.Approved
AtenololDemecarium may increase the bradycardic activities of Atenolol.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Demecarium.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Demecarium.Approved, Vet Approved
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Demecarium.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Demecarium.Approved, Investigational
BefunololDemecarium may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Demecarium.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Demecarium.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Demecarium.Approved, Vet Approved
BetaxololDemecarium may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Demecarium is combined with Bethanechol.Approved
BevantololDemecarium may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Demecarium.Approved
BisoprololDemecarium may increase the bradycardic activities of Bisoprolol.Approved
BopindololDemecarium may increase the bradycardic activities of Bopindolol.Approved
BucindololDemecarium may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Demecarium.Approved
BufuralolDemecarium may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololDemecarium may increase the bradycardic activities of Bupranolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Demecarium is combined with Carbachol.Approved
CarteololDemecarium may increase the bradycardic activities of Carteolol.Approved
CarvedilolDemecarium may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololDemecarium may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Demecarium is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Demecarium.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Demecarium.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Demecarium.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Demecarium.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Demecarium.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Demecarium.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Demecarium.Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Demecarium.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Demecarium.Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Demecarium.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Demecarium.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Demecarium.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Demecarium.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Demecarium.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Demecarium.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Demecarium.Withdrawn
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Demecarium.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Demecarium.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Demecarium.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Demecarium.Approved
DipyridamoleThe therapeutic efficacy of Demecarium can be decreased when used in combination with Dipyridamole.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Demecarium is combined with EPIBATIDINE.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Demecarium.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Demecarium.Approved
EsmololDemecarium may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Demecarium.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Demecarium.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Demecarium.Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Demecarium.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Demecarium.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Demecarium.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Demecarium.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Demecarium.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Demecarium.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Demecarium.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Demecarium.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Demecarium.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Demecarium.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Demecarium.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Demecarium.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Demecarium.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Demecarium.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Demecarium.Approved, Investigational, Withdrawn
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Demecarium.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Demecarium.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Demecarium is combined with GTS-21.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Demecarium.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Demecarium.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Demecarium.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Demecarium.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Demecarium.Approved
IndenololDemecarium may increase the bradycardic activities of Indenolol.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Demecarium.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Demecarium.Investigational
LabetalolDemecarium may increase the bradycardic activities of Labetalol.Approved
LevobunololDemecarium may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Demecarium is combined with Lobeline.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Demecarium.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Demecarium.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Demecarium.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Demecarium.Vet Approved
MethacholineThe risk or severity of adverse effects can be increased when Demecarium is combined with Methacholine.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Demecarium.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Demecarium.Approved, Vet Approved
MetipranololDemecarium may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Demecarium.Approved
MetoprololDemecarium may increase the bradycardic activities of Metoprolol.Approved, Investigational
MivacuriumDemecarium may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Demecarium.Approved, Vet Approved
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Demecarium.Vet Approved
NadololDemecarium may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Demecarium.Investigational
NicotineThe risk or severity of adverse effects can be increased when Demecarium is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Demecarium is combined with Nicotine bitartrate.Approved
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Demecarium.Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Demecarium.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Demecarium.Approved
OxprenololDemecarium may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Demecarium.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Demecarium.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Demecarium.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Demecarium.Approved
PenbutololDemecarium may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Demecarium.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Demecarium is combined with Pilocarpine.Approved
PindololDemecarium may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Demecarium.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Demecarium.Approved
PractololDemecarium may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Demecarium.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Demecarium.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Demecarium.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Demecarium.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Demecarium.Experimental
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Demecarium.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Demecarium.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Demecarium.Investigational
PropranololDemecarium may increase the bradycardic activities of Propranolol.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Demecarium.Approved
RapacuroniumDemecarium may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Demecarium.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Demecarium.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Demecarium.Approved
SotalolDemecarium may increase the bradycardic activities of Sotalol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Demecarium.Approved
TimololDemecarium may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Demecarium.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Demecarium.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Demecarium.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Demecarium.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Demecarium.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Demecarium.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Demecarium.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Demecarium.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Demecarium.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Demecarium.Approved
VareniclineThe risk or severity of adverse effects can be increased when Demecarium is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Demecarium.Approved
Food InteractionsNot Available
References
Synthesis Reference

Schrnid, O.; US. Patent 2,789,981; April 23, 1957; assigned to Oesterreichische Stickstoffwerke AG, Austria.

General References
  1. Ward DA, Abney K, Oliver JW: The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5. [PubMed:12641839 ]
  2. Krohne SG: Effect of topically applied 2% pilocarpine and 0.25% demecarium bromide on blood-aqueous barrier permeability in dogs. Am J Vet Res. 1994 Dec;55(12):1729-33. [PubMed:7887518 ]
  3. Gum GG, Gelatt KN, Gelatt JK, Jones R: Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma. Am J Vet Res. 1993 Feb;54(2):287-93. [PubMed:8430939 ]
External Links
ATC CodesS01EB04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.975
Blood Brain Barrier+0.8552
Caco-2 permeable+0.5237
P-glycoprotein substrateSubstrate0.6145
P-glycoprotein inhibitor INon-inhibitor0.778
P-glycoprotein inhibitor IIInhibitor0.6802
Renal organic cation transporterNon-inhibitor0.6822
CYP450 2C9 substrateNon-substrate0.7289
CYP450 2D6 substrateNon-substrate0.7984
CYP450 3A4 substrateSubstrate0.707
CYP450 1A2 substrateNon-inhibitor0.8801
CYP450 2C9 inhibitorNon-inhibitor0.8903
CYP450 2D6 inhibitorNon-inhibitor0.9166
CYP450 2C19 inhibitorNon-inhibitor0.8855
CYP450 3A4 inhibitorNon-inhibitor0.88
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8541
Ames testNon AMES toxic0.6225
CarcinogenicityNon-carcinogens0.684
BiodegradationNot ready biodegradable0.9618
Rat acute toxicity2.5848 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7692
hERG inhibition (predictor II)Inhibitor0.5084
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point164-170Schrnid, O.; US. Patent 2,789,981; April 23, 1957; assigned to Oesterreichische Stickstoffwerke AG, Austria.
logP-1.75Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.69e-05 mg/mLALOGPS
logP0.65ALOGPS
logP-1.4ChemAxon
logS-7.6ALOGPS
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.08 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity185.71 m3·mol-1ChemAxon
Polarizability64.49 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as substituted anilines. These are organic compound containing an aniline group substituted at one or more positions.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilines
Direct ParentSubstituted anilines
Alternative Parents
Substituents
  • Substituted aniline
  • Dicarboxylic acid or derivatives
  • Tertiary amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Organic cation
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Ward DA, Abney K, Oliver JW: The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5. [PubMed:12641839 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Meiniel R: Neuromuscular blocking agents and axial teratogenesis in the avian embryo. Can axial morphogenetic disorders by explained by pharmacological action upon muscle tissue? Teratology. 1981 Apr;23(2):259-71. [PubMed:7196602 ]
  2. Gum GG, Gelatt KN, Gelatt JK, Jones R: Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma. Am J Vet Res. 1993 Feb;54(2):287-93. [PubMed:8430939 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23